This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Gilead (GILD) Veklury Retains Activity Against Omicron Variant
by Zacks Equity Research
Gilead's (GILD) Veklury (remdesivir) retains antiviral activity against Omicron, Delta and other emergent SARS-CoV-2 variants in multiple in vitro studies.
Lilly's (LLY) COVID-19 Drug Gets FDA Nod for Emergency Use
by Zacks Equity Research
Lilly's (LLY) new antibody-drug, bebtelovimab is authorized to treat certain non-hospitalized adults and pediatric patients with mild-to-moderate COVID-19 who are at high risk of progressing to severe disease
The Zacks Analyst Blog Highlights: Pfizer, AstraZeneca, Glaxo, Sanofi's and Eli Lilly
by Zacks Equity Research
Pfizer, AstraZeneca, Glaxo, Sanofi¿¿¿s and Eli Lilly are highlighted in this Analyst Blog.
The Zacks Analyst Blog Highlights: Eli Lilly and Company, Union Pacific Corporation, and Freeport-McMoRan Inc
by Zacks Equity Research
Eli Lilly and Company, Union Pacific Corporation, and Freeport-McMoRan Inc. are highlighted in this Analyst Blog.
Top Stock Reports for Eli Lilly, Union Pacific & Freeport-McMoRan
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Union Pacific Corporation (UNP), and Freeport-McMoRan Inc. (FCX).
Lilly (LLY) Gets FDA Panel Advice for New Study on Sintilimab
by Zacks Equity Research
An FDA advisory for Lilly's (LLY) partner Innovent Biologics calls for conducting a new study on its first-line lung cancer candidate, sintilimab, for gaining approval for the same in the United States.
Pharma Stock Roundup: PFE, AZN, GSK's Q4 Earnings, FDA Updates for SNY, LLY
by Kinjel Shah
Pfizer (PFE), AstraZeneca (AZN) and Glaxo (GSK) report fourth-quarter results. FDA approves Sanofi's (SNY) new rare blood disorder drug.
Vir (VIR) Announces Encouraging Data on COVID-19 Antibody
by Zacks Equity Research
Vir (VIR), Glaxo's sotrovimab retains neutralizing activity against the BA.2 subvariant of Omicron, per preclinical data.
Incyte (INCY) Q4 Earnings Miss, Sales Beat on Jakafi, Royalties
by Zacks Equity Research
Incyte's (INCY) earnings miss, but revenues surpass estimates in the fourth quarter on higher royalty revenues and increased Jakafi sales.
Amgen's (AMGN) Q4 Earnings Top Estimates, Product Sales Fall
by Zacks Equity Research
Amgen (AMGN) beats Q4 estimates for earnings but misses the same for sales. Higher Other Revenue for manufacturing Eli Lilly's COVID-19 antibody boost sales growth.
Sanofi's (SNY) Enjaymo Gets FDA Nod For Rare Blood Disorder
by Zacks Equity Research
The FDA approves Sanofi's (SNY) Enjaymo for the treatment of hemolysis in adult patients with cold agglutinin disease. Enjaymo is the first therapy to be approved for this indication.
The Zacks Analyst Blog Highlights: AbbVie, Merck, Eli Lilly, Novartis and Pfizer
by Zacks Equity Research
AbbVie, Merck, Eli Lilly, Novartis and Pfizer are included in this analyst blog.
How Will Pfizer's (PFE) Key Drugs Perform in Q4 Earnings?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis (alliance revenue), Xtandi and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the fourth quarter.
Pharma Stock Roundup: MRK, LLY, ABBV Post Q4 Earnings, PFE Ends Vupanorsen Program
by Kinjel Shah
AbbVie (ABBV), Merck (MRK), Eli Lilly (LLY) and Novartis (NVS) report fourth-quarter results. Pfizer (PFE) ends vupanorsen development.
Sanofi (SNY) Q4 Earnings Beat, Vaccines Hurt Sales Growth
by Zacks Equity Research
Sanofi (SNY) beats fourth-quarter estimates for earnings but misses the same for sales. Dupixent drives sales growth, offsetting lower vaccine sales.
Eli Lilly (LLY) Q4 Earnings Miss, COVID Therapies Aid Sales
by Zacks Equity Research
Eli Lilly (LLY) misses earnings estimates in the fourth quarter while revenues beat the same. Stock down in pre-market trading.
Merck (MRK) Q4 Earnings & Sales Beat, COVID Drug Adds $952M
by Zacks Equity Research
Merck (MRK) beats Q4 estimates for earnings and sales. The company anticipates robust growth in revenues and income to continue in 2022.
Novo Nordisk's (NVO) Q4 Earnings and Sales Beat Estimates
by Zacks Equity Research
Novo Nordisk's (NVO) earnings and revenues beat estimates in Q4. Sales are driven by growth in Diabetes and Obesity Care on higher GLP-1 revenues.
Drug/Biotech Stocks Earnings on Feb 3: BIIB, LLY & MRK
by Zacks Equity Research
Let us take a look at three drug/biotech companies, namely, BIIB, LLY and MRK, which are gearing up for their earnings release.
Novartis (NVS) Q4 Earnings & Sales Miss, Sandoz Review Ongoing
by Zacks Equity Research
Novartis (NVS) reports dismal results for the fourth quarter. Key brands maintain momentum but the generics business remains weak.
Eli Lilly (LLY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) fourth-quarter sales.
Pfizer (PFE) Ends Vupanorsen Development, Returns Rights to Ionis
by Zacks Equity Research
Pfizer (PFE) returns development rights to Ionis for the investigational antisense therapy, vupanorsen.
Pfizer (PFE) Lorviqua Gets EU Nod for First-Line Lung Cancer
by Zacks Equity Research
The European Commission approves label expansion of Pfizer's (PFE) Lorviqua as a first-line treatment for ALK-positive non-small cell lung cancer.
Lilly (LLY) Stops Lupus Study, Expects CRL for Olumiant in Eczema
by Zacks Equity Research
While Eli Lilly (LLY) and Incyte (INCY) have decided to discontinue the development of JAK inhibitor Olumiant in lupus indication, they expect a complete response letter from the FDA for Olumiant in atopic dermatitis.
Pfizer (PFE) Gets CHMP Recommendation for COVID Pill Paxlovid
by Zacks Equity Research
Pfizer's (PFE) oral COVID-19 drug, Paxlovid, gets recommendation from the CHMP for its authorization in Europe for treating mild-to-moderate COVID-19 in patients at increased risk of hospitalizations.